Inactive Instrument

Company Correvio Pharma Corp Toronto S.E.

Equities

CA14159U3010

Pharmaceuticals

Business Summary

Correvio Pharma Corp is a Canada-based company, which is a specialty pharmaceutical company. The Company focused on providing acute services. It's portfolio brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. The Company's products include Trevyent, a drug-device combination that is designed to deliver treprostinil, the treatment for pulmonary arterial hypertension.

Members of the board

Members of the board TitleAgeSince
Director/Board Member - -
Director/Board Member 53 -
Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,191,487 57,073,696 ( 86.23 %) 0 86.23 %

Company contact information

Correvio Pharma Corp.

333 Bay Street Suite 2400

M5H 2T6, Toronto

+

http://cardiome.com
address Correvio Pharma Corp